Treatment of Intramuscular Abscess Caused by Tuberculosis

Initial Treatment Regimen

The European Respiratory Society recommends treating intramuscular TB abscess with a standard 6-month four-drug regimen: rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 months 1, 2, 3
The intensive phase consists of rifampicin, isoniazid, pyrazinamide, and ethambutol daily for 2 months, as recommended by the European Respiratory Society 1
All four drugs must be given together during the intensive phase to prevent drug resistance development, as stated by the Clinical Infectious Diseases journal 4

For confirmed isoniazid-resistant TB, the American Journal of Respiratory and Critical Care Medicine recommends adding a later-generation fluoroquinolone (levofloxacin or moxifloxacin) to rifampicin, ethambutol, and pyrazinamide for 6 months 5, 6
For multidrug-resistant TB (MDR-TB), the European Respiratory Journal recommends using at least three Group A agents (bedaquiline, linezolid, levofloxacin/moxifloxacin) plus additional agents to ensure at least four effective drugs 7

The European Respiratory Society recommends implementing directly observed therapy (DOT) to ensure every dose is witnessed, which has demonstrated improved cure rates, reduced rates of drug resistance and relapse, and better outcomes in non-compliant populations 1, 8, 3
Clinical monitoring should include assessment for symptom improvement and monthly evaluation for drug adverse effects, as recommended by the Clinical Infectious Diseases journal and Praxis Medical Insights 3, 4

For HIV co-infection, the European Respiratory Society recommends using the same standard 6-month regimen, but treatment should be extended to at least 9 months if clinical or bacteriologic response is slow, as stated by Praxis Medical Insights 1, 3
For pregnancy, the Thorax journal recommends standard treatment with all first-line drugs (rifampicin, isoniazid, pyrazinamide, ethambutol), which is safe, and avoiding streptomycin due to fetal ototoxicity 8, 2

The Clinical Infectious Diseases journal recommends never adding a single drug to a failing regimen, as this creates de facto monotherapy and rapidly generates drug resistance, and instead adding at least two drugs to which the organism is susceptible 4
The MMWR Recommendations and Reports recommends never stopping treatment prematurely, and instead basing the decision to stop on the number of doses taken within the maximum treatment period 9